Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(5 years from now) | |
US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 21, 2027 |
NCE-1 date: 2026-09-21
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
9
European Union
8
United States
5
Japan
3
Canada
3
Spain
3
Korea, Republic of
3
China
2
Brazil
2
Portugal
2
Denmark
2
France
2
Poland
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic